QurAlis Doses First Patient With ALS in Phase 1 Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS

QRL-101 is the only Kv7 ion channel opener being actively studied for the treatment of hyperexcitability-induced disease progression in ALS, which occurs in nearly 50 percent of patients Kv7 is a clinically validated target to regulate hyperexcitable state in epilepsy QurAlis’ Phase 1…